Effects of SGLT2 inhibitors across the spectrum of albuminuria in cardiovascular–kidney–metabolic conditions: A pooled analysis of randomised trials

Albuminuria is associated with an increased risk of cardiovascular and kidney events. Sodium glucose co‐transporter 2 inhibitors (SGLT2i) reduce albuminuria and improve kidney outcomes in patients with albuminuric chronic kidney disease (CKD). Patients with low‐ or without albuminuria have been underrepresented in randomised clinical trials (RCTs), and the effects of SGLT2i on cardiovascular and kidney outcomes across the full range of albuminuria require further investigation.

• Publication year

  2025

• Venue

  Diabetes, obesity and metabolism

• Publication date

  2025-11-10

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/dom.70289PMID 41208574PMCID 12803639
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• MRAs, SGLT2 Inhibitors, and Kidney Outcomes in CKD and HF: Differences in Diseases, Drugs, or Both?

  2025cited by this paper
• Albuminuria Is the Key Driver of Kidney Benefit with Aldosterone Receptor Antagonists in Type 2 Diabetes.

  2025cited by this paper
• Effects of SGLT2 inhibitors across the spectrum of albuminuria in cardiovascular–kidney–metabolic conditions: A pooled analysis of randomised trials

  2025cited by this paper
• Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes.

  2025cited by this paper
• Mineralocorticoid Receptor Antagonist Combined with SGLT2 Inhibitor versus SGLT2 Inhibitor Alone in Chronic Kidney Disease: A Meta-Analysis of Randomized Trials

  2024cited by this paper
• A 4-Variable Model to Predict Cardio-Kidney Events and Mortality in Chronic Kidney Disease: The Chronic Renal Insufficiency Cohort (CRIC) Study

  2023cited by this paper
• Albuminuria as a marker of systemic congestion in patients with heart failure

  2022cited by this paper
• Dapagliflozin and Kidney Outcomes in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Analysis of the DELIVER Randomized Clinical Trial.

  2022cited by this paper
• Association of Empagliflozin Treatment With Albuminuria Levels in Patients With Heart Failure

  2022cited by this paper
• Influence of endpoint definitions on the effect of empagliflozin on major renal outcomes in the EMPEROR‐Preserved trial

  2021cited by this paper
• SGLT2 inhibitors: renal outcomes according to baseline albuminuria

  2021cited by this paper
• Empagliflozin in Heart Failure with a Preserved Ejection Fraction.

  2021cited by this paper
• Empagliflozin and Major Renal Outcomes in Heart Failure.

  2021cited by this paper
• Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial.

  2021cited by this paper
• Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction

  2020cited by this paper
• The Potential of Albuminuria as a Biomarker of Diabetic Complications

  2020cited by this paper
• Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure

  2020cited by this paper
• Dapagliflozin in Patients with Chronic Kidney Disease.

  2020cited by this paper
• SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis.

  2019cited by this paper
• Evaluation of the effects of sodium–glucose co‐transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR‐Preserved Trial

  2019cited by this paper
• Aldosterone induces albuminuria via matrix metalloproteinase-dependent damage of the endothelial glycocalyx.

  2019cited by this paper
• Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Renal Outcomes in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

  2019cited by this paper
• SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.

  2019cited by this paper
• Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.

  2019cited by this paper
• Canagliflozin and cardiovascular and renal events in type 2 diabetes

  2018cited by this paper
• Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study–Renal (CANVAS‐R): A randomized, placebo‐controlled trial

  2017cited by this paper
• Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial.

  2017cited by this paper
• Albuminuria changes are associated with subsequent risk of end-stage renal disease and mortality.

  2017cited by this paper
• The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics

  2017cited by this paper
• Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

  2017cited by this paper
• Dapagliflozin reduces albuminuria in patients with diabetes and hypertension receiving renin‐angiotensin blockers

  2016cited by this paper
• Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.

  2016cited by this paper
• Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.

  2015cited by this paper
• Focus on renal congestion in heart failure

  2015cited by this paper
• Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME™)

  2014cited by this paper
• Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis.

  2012cited by this paper
• Does Evidence Support ReninAngiotensin System Blockade for Slowing Nephropathy Progression in Elderly Persons?

  2009cited by this paper
• Decreased cardiac output, venous congestion and the association with renal impairment in patients with cardiac dysfunction

  2007cited by this paper
• Low-Grade Albuminuria and Incidence of Cardiovascular Disease Events in Nonhypertensive and Nondiabetic Individuals: The Framingham Heart Study

  2005cited by this paper
• The relationship of cardiovascular risk factors to microalbuminuria in older adults with or without diabetes mellitus or hypertension: the cardiovascular health study.

  2004cited by this paper

• Chronic Kidney Disease in Metabolic Disease: Regulation of SGLT2 and Transcriptomic–Epigenetic Effects of Its Pharmacological Inhibition

  2026cites this paper
• Non-albumin proteinuria is associated with all-cause mortality in community-dwelling adults.

  2026cites this paper
• Effects of SGLT2 inhibitors across the spectrum of albuminuria in cardiovascular–kidney–metabolic conditions: A pooled analysis of randomised trials

  2025cites this paper